Literature DB >> 3433235

Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis.

P B Davis1, K Vargo.   

Abstract

Parents of children with cystic fibrosis have been reported to have a high prevalence of increased airway reactivity, but these studies were done in a select young, healthy, symptomless population. In the present study respiratory symptoms were examined in 315 unselected parents of children with cystic fibrosis and 162 parents of children with congenital heart disease (controls). The cardinal symptom of airway reactivity, wheezing, was somewhat more prevalent in cystic fibrosis parents than in controls, but for most subgroups this increased prevalence did not reach statistical significance. Among those who had never smoked, 38% of obligate heterozygotes for cystic fibrosis but only 25% of the controls reported wheezing (p less than 0.05). The cystic fibrosis parents who had never smoked but reported wheezing had lower FEV1 and FEF25-75, expressed as a percentage of the predicted value, than control parents; and an appreciable portion of the variance in pulmonary function was contributed by the interaction of heterozygosity for cystic fibrosis with wheezing. For cystic fibrosis parents, but not controls, the complaint of wheezing significantly contributed to the prediction of pulmonary function (FEV1 and FEF25-75). In addition, parents of children with cystic fibrosis reported having lung disease before the age of 16 more than twice as frequently as control parents. Other respiratory complaints, including dyspnoea, cough, bronchitis, and hay fever, were as common in controls as in cystic fibrosis heterozygotes. These data are consistent with the hypothesis that heterozygosity for cystic fibrosis is associated with increased airway reactivity and its symptoms, and that the cystic fibrosis heterozygotes who manifest airway reactivity and its symptoms may be at risk for poor pulmonary function.

Entities:  

Mesh:

Year:  1987        PMID: 3433235      PMCID: PMC460638          DOI: 10.1136/thx.42.2.120

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

1.  Chronic bronchitis and mucoviscidosis.

Authors:  E BERNARD; L ISRAEL; M M DEBRIS
Journal:  Am Rev Respir Dis       Date:  1962-01

2.  Mucoviscidosis as a factor in chronic lung disease in adults.

Authors:  A J KARLISH; A L TARNOKY
Journal:  Lancet       Date:  1960-09-03       Impact factor: 79.321

3.  Absence of detrimental effect of the carrier state for the cystic fibrosis gene.

Authors:  W Y Hallett; A G Knudson; F J Massey
Journal:  Am Rev Respir Dis       Date:  1965-11

4.  Increased levels of airways responsiveness as a risk factor for development of chronic obstructive lung disease. What are the issues?

Authors:  S T Weiss; F E Speizer
Journal:  Chest       Date:  1984-07       Impact factor: 9.410

5.  Airways reactivity and functional deterioration in relatives of COPD patients.

Authors:  E J Britt; B Cohen; H Menkes; E Bleecker; S Permitt; R Rosenthal; P Norman
Journal:  Chest       Date:  1980-02       Impact factor: 9.410

6.  Airways reactivity and the need for a simple test.

Authors:  H A Menkes
Journal:  Am Rev Respir Dis       Date:  1980-04

7.  Epidemiology Standardization Project (American Thoracic Society).

Authors:  B G Ferris
Journal:  Am Rev Respir Dis       Date:  1978-12

8.  Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection.

Authors:  D W Empey; L A Laitinen; L Jacobs; W M Gold; J A Nadel
Journal:  Am Rev Respir Dis       Date:  1976-02

9.  Observations on (i) sweat sodium levels in relation to chronic respiratory disease in adults and (ii) the incidence of respiratory and other disease in parents and siblings of patients with fibrocystic disease of the pancreas.

Authors:  C M ANDERSON; M FREEMAN; J ALLAN; L HUBBARD
Journal:  Med J Aust       Date:  1962-06-23       Impact factor: 7.738

10.  The relationship of childhood respiratory illness to adult obstructive airway disease.

Authors:  B Burrows; R J Knudson; M D Lebowitz
Journal:  Am Rev Respir Dis       Date:  1977-05
View more
  4 in total

1.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.

Authors:  P W Miller; A Hamosh; M Macek; P A Greenberger; J MacLean; S M Walden; R G Slavin; G R Cutting
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  A highly sensitive method for analysis of 7-dehydrocholesterol for the study of Smith-Lemli-Opitz syndrome.

Authors:  Wei Liu; Libin Xu; Connor Lamberson; Dorothea Haas; Zeljka Korade; Ned A Porter
Journal:  J Lipid Res       Date:  2013-11-20       Impact factor: 5.922

Review 3.  Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?

Authors:  V Witko-Sarsat; I Sermet-Gaudelus; G Lenoir; B Descamps-Latscha
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

4.  CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons.

Authors:  Xi Zhang; Camille M Moore; Laura D Harmacek; Joanne Domenico; Vittobai Rashika Rangaraj; Justin E Ideozu; Jennifer R Knapp; Katherine J Woods; Stephanie Jump; Shuang Jia; Jeremy W Prokop; Russell Bowler; Martin J Hessner; Erwin W Gelfand; Hara Levy
Journal:  JCI Insight       Date:  2022-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.